ForPatients

by Roche

Age-Related Macular Degeneration

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)

Trial Status Trial Runs In Trial Identifier
Completed 1 Countries NCT02510794 GX28228

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase II multicenter, dose-ranging, randomized, active treatment (monthly ITV injection)-controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three ranibizumab formulation arms (10 mg/mL, 40 mg/mL, and 100 mg/mL) compared with the control arm (0.5-mg monthly ITV injections of 10-mg/mL formulation) in participants with subfoveal neovascular age-related macular degeneration (nAMD).

Genentech, Inc. Sponsor		Phase 2 Phase		
NCT02510794 GX28228 Trial Identifiers				
Eligibility Criteria:				
Gender All	Age >=50 Years		Healthy Volunteers No	